|
NR 7-9/2008
|
|
|
|
|
|
|
|
|
Skuteczność i
bezpieczeństwo stosowania bevacizumabu w leczeniu wysiękowego
zwyrodnienia plamki związanego z wiekiem
Safety and efficacy of using
bevacizumab in the treatment of exudative age-related macular
degeneration
Maria Muzyka-Woźniak1,2,
Jolanta Oficjalska-Młyńczak1,2, Bożena Gołębiowska1
1 Z Ośrodka Okulistyki Klinicznej NZOZ „Spektrum”
Kierownik: prof. dr hab. n. med. Maria Hanna Niżankowska
2 Z Katedry i Kliniki Okulistyki Akademii Medycznej
we Wrocławiu
Kierownik: dr hab. n. med. Marta Misiuk-Hojło |
|
|
| Summary: |
Purpose: To
evaluate the efficacy and safety of intravitreal
bevacizumab administered on “as required” basis in
patients with exudative age-related macular degeneration
(AMD).
Material and methods: A prospective uncontrolled
cohort study of patients with exudative AMD treated with
intravitreal bevacizumab administered “as required”
based on PRONTO reinjection criteria. Main outcome
measures include standardized best-corrected visual
acuity (BCVA) and central macular thickness (CMT)
measured with optical coherence tomography (Stratus OCT).
Results: 153 eyes of 153 consecutive patients
with AMD were treated with intravitreal bevacizumab
injection, followed monthly and reinjected “as required”.
Mean follow-up time was 14.2 weeks (4-52 weeks).
Distance BCVA improved from 0.79 log MAR at baseline to
0.69 at 4 weeks, 0.7 at 8 weeks, 0.64 at 12 weeks, 0.71
at 16 weeks and 0.63 at 20 weeks (p<.05). Near BCVA
improved from 0.13 at baseline to 0.22 at 4 and 8 weeks,
0.25 at 12 weeks, 0.22 at 16 weeks and 0.28 at 20 weeks
(p<.05). Mean CMT decreased from 395 microm at baseline
to 265 at 4 weeks, 260 at 8 weeks, 268 at 12 weeks, 255
at 16 weeks and 257 at 20 weeks (p<.05). Mean time
between first and second injection was 91.9 days, and
between second and third injection 99.7 days. No adverse
events were observed.
Conclusions: Short-term results suggest that
intravitreal bevaciuzmab administered “as required” is
safe and effective in patients with exudative AMD. “As
required” schedule may decrease the risk of adverse
events and lower the cost of treatment. |
| Słowa kluczowe: |
bevacizumab (Avastin),
zwyrodnienie plamki związane z wiekiem (AMD), optyczna
koherentna tomografia (OCT), naczyniowy śródbłonkowy
czynnik wzrostu (VEGF). |
| Key words: |
bevacizumab (Avastin),
age-related macular degenearation (AMD), optical
coherence tomography (OCT), vascular endothelial growth
factor (VEGF). |
|
|
|
|
|
|
